Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.

In this case report, a 4-year-old with neurofibromatosis type 1 experienced significant reduction in an inoperable periorbital plexiform neurofibroma and visual improvement following treatment with selumetinib.

Isotretinoin can raise CPK levels, so patients need monitoring, especially before surgery.

This review highlights that while sonidegib and vismodegib offer promising treatment options for advanced basal cell carcinoma, their use is often limited by treatment-emergent adverse events, which can be managed through protocol modifications and supportive interventions.

This article reports a case of rhabdomyolysis in a patient two hours after consuming the freshwater fish Mylossoma duriventre, suggesting a possible link to Haff disease from an unidentified toxin.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

Hair loss may be linked to cardiovascular health problems.

This article reviews sPLA2-mediated phospholipid metabolism using sPLA2 transgenic/knockout mice and lipid mass spectrometry, offering insights into the distinct roles of sPLA2 enzymes in various biological events.

This review highlights the potential of microneedle technology in traditional Chinese medicine as a promising transdermal delivery system for skin diseases, showcasing improved efficacy and reduced side effects of TCM ingredients while discussing the challenges of its clinical application.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

This study found that an anti-atopic lotion containing fucoidan helped heal skin damage in hairless mice with atopic dermatitis by reducing skin thickness and modulating immune responses.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

This study highlights that azelaic acid, initially recognized for skin hypopigmentation, shows potential in treating various skin conditions due to its complex mechanisms, even though these are not yet fully understood, indicating a need for further research.

Managing metabolic syndrome needs both lifestyle changes and medical treatments.

This study suggests that in mice, plasmalogens may enhance hair growth by activating TRPC4 channels, which increases calcium influx and subsequently stimulates AMPK in hair follicles.

This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.

This review discusses the potential impact of lifestyle factors on the progression of androgenetic alopecia and reports no new clinical findings; the authors emphasize the need for more comprehensive studies.

This review highlights the potential of wedelolactone from the plant Wedelia Chinensis, summarizing its reported pharmacological effects, including anti-inflammatory, antiviral, antibacterial, antitumor, anti-osteoporosis activities, and organ protection based on existing in vitro and in vivo research findings.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

This article discusses laboratory and physical markers that may help detect androgenic anabolic steroid abuse in athletes and reports no new primary research results.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

This review explores the medicinal properties of Eclipta alba and its phytoconstituents and reports their potential for developing new drugs, but presents no new research results.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

This article reviews sebaceous immunobiology and highlights the complex role of sebaceous glands and sebocytes in skin barrier function and inflammation, particularly in acne pathogenesis, but reports no new results.